Literature DB >> 1743159

Computerized analysis of EEG background activity in epileptic patients.

T Miyauchi1, K Endo, T Yamaguchi, H Hagimoto.   

Abstract

Background activity was studied in 128 idiopathic epilepsy patients and 30 normal controls using EEG topography and t-statistic significance probability mapping (t-SPM). In epileptic patients, EEG background activity showed a marked increase in delta, theta, alpha 1, and beta 1, and a decrease in alpha 2 activity as compared with controls. Untreated epileptic patients had a significant increase in delta, theta, and alpha 1 as compared with controls. For epileptic patients treated with antiepileptic drugs (AEDs), the most marked slowing was observed in the polytherapy group, followed by the monotherapy group and then the untreated group. Among seizure types, patients with partial seizures (PS) tended to exhibit more slowing than patients with only generalized tonic-clonic seizures (GTC). Moreover, PS had a right-left asymmetry in alpha 2 and beta 1 activities. In a comparison of AEDs, patients receiving carbamazepine (CBZ) and phenobarbital (PB) showed no significant difference as compared with the untreated group. In contrast, patients receiving valproate (VPA) showed a decrease in slow and fast activities. EEG changes associated with each AED were different in GTC and PS. Patients receiving VPA for GTC showed a decrease in theta and beta 1 activities, but those with PS showed a decrease only in delta activity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1743159     DOI: 10.1111/j.1528-1157.1991.tb05544.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  8 in total

1.  Persistent abnormality detected in the non-ictal electroencephalogram in primary generalised epilepsy.

Authors:  J O Willoughby; S P Fitzgibbon; K J Pope; L Mackenzie; A V Medvedev; C R Clark; M P Davey; R A Wilcox
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-01       Impact factor: 10.154

Review 2.  Medical diagnostic decision support systems--past, present, and future: a threaded bibliography and brief commentary.

Authors:  R A Miller
Journal:  J Am Med Inform Assoc       Date:  1994 Jan-Feb       Impact factor: 4.497

3.  Photosensitive epilepsy is associated with reduced inhibition of alpha rhythm generating networks.

Authors:  Anna Elisabetta Vaudano; Andrea Ruggieri; Pietro Avanzini; Giuliana Gessaroli; Gaetano Cantalupo; Antonietta Coppola; Sanjay M Sisodiya; Stefano Meletti
Journal:  Brain       Date:  2017-04-01       Impact factor: 13.501

4.  A decision support framework for the discrimination of children with controlled epilepsy based on EEG analysis.

Authors:  Vangelis Sakkalis; Tracey Cassar; Michalis Zervakis; Ciprian D Giurcaneanu; Cristin Bigan; Sifis Micheloyannis; Kenneth P Camilleri; Simon G Fabri; Eleni Karakonstantaki; Kostas Michalopoulos
Journal:  J Neuroeng Rehabil       Date:  2010-06-02       Impact factor: 4.262

5.  Slower alpha rhythm associates with poorer seizure control in epilepsy.

Authors:  Eugenio Abela; Adam D Pawley; Chayanin Tangwiriyasakul; Siti N Yaakub; Fahmida A Chowdhury; Robert D C Elwes; Franz Brunnhuber; Mark P Richardson
Journal:  Ann Clin Transl Neurol       Date:  2018-12-18       Impact factor: 4.511

6.  Dynamic coupling between the central and autonomic cardiac nervous systems in patients with refractory epilepsy: A pilot study.

Authors:  Eline Melo; José Fiel; Rodrigo Milhomens; Thaynara Ribeiro; Raphael Navegantes; Francinaldo Gomes; Bruno Duarte Gomes; Antonio Pereira
Journal:  Front Neurol       Date:  2022-08-10       Impact factor: 4.086

7.  Gamma power is phase-locked to posterior alpha activity.

Authors:  Daria Osipova; Dora Hermes; Ole Jensen
Journal:  PLoS One       Date:  2008-12-22       Impact factor: 3.240

8.  Interval analysis of interictal EEG: pathology of the alpha rhythm in focal epilepsy.

Authors:  Jan Pyrzowski; Mariusz Siemiński; Anna Sarnowska; Joanna Jedrzejczak; Walenty M Nyka
Journal:  Sci Rep       Date:  2015-11-10       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.